Celltrion Brings AI and ADCs to the BIO Stage as Korean Biotech Giant Looks for Its Next Growth Curve
As the biosimilars market gradually matures, Celltrion emphasized AI drug discovery and antibody-drug conjugate capabilities at BIO USA, signaling not just a technology showcase but how a large biotech company is reorganizing R&D risk and its future pipeline.